Retrospective analysis on efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in advanced or recurrent colorectal cancer

Natsuko Chiba, Takashi Yoshioka, Shunsuke Kato, Shin Takahashi, Hiroyuki Shibata, Satoshi Kato, Masato Sakayori, Kazunori Otsuka, Yuichi Kakudo, Hisatsugu Ohori, Gengo Yamaura, Masanobu Takahashi, Katsuhiro Yasuda, Chikashi Ishioka

Research output: Contribution to journalArticle

Abstract

The aim of this study was to evaluate the efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (I-LV) in 50 patients with advanced or recurrent colorectal cancer in our institute. The dose of 5-FU was 600 mg/m2 and the dose of l-LV was 250 mg/m2. Objective response were 36.8% of patients who had administration of full-dose and 14.8% of patients who had the administration of reduced dose or prolonged interval. No significant difference was observed in clinical benefit rates between patients administrated in full-dose and patients in reduced dose or prolonged interval. Median survival time (MST) of patients in reduced dose or prolonged interval is longer than patients in full-dose. These data suggest that 5-FU/l-LV can be given in the outpatient and yields improved prognosis and minimal adverse reactions even in patients in reduced dose or prolonged interval.

Original languageEnglish
Pages (from-to)991-995
Number of pages5
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume32
Issue number7
Publication statusPublished - 2005 Jul

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Retrospective analysis on efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in advanced or recurrent colorectal cancer'. Together they form a unique fingerprint.

  • Cite this